Xammy Nguyenla

  • Current Program Year: MS1
  • M.D./Ph.D. Program Students, School of Medicine

Biography

Research interests: Host-pathogen interactions, immunology, microbiology, cell biology, Mycobacterium tuberculosis, SARS-CoV-2, vaccines, small molecule therapeutics, and non-human primate models and clinical trials.

Clinical interests: family medicine, primary care, internal medicine, immunology, infectious disease, global health, tropical medicine, pulmonology, and pathology.

Education and training

  • Degrees

    • B.A., 2019, University of California, Berkeley

Additional information

Publications

Selected publications

  • Graham TGW, Dugast-Darzacq C, Dailey GM, Nguyenla XH, Van Dis E, Esbin MN, Abidi A, Stanley SA, Darzacq X, Tjian R. Open-source RNA extraction and RT-qPCR methods for SARS-CoV-2 detection. PLoS One. 2021 Feb 3;16(2):e0246647. doi: 10.1371/journal.pone.0246647. PMID: 33534838; PMCID: PMC7857565.
  • Jong RM, Van Dis E, Berry SB, Nguyenla X, Baltodano A, Pastenkos G, Xu C, Fox D, Yosef N, McWhirter SM, Stanley SA. Mucosal Vaccination with Cyclic Dinucleotide Adjuvants Induces Effective T Cell Homing and IL-17-Dependent Protection against Mycobacterium tuberculosis Infection. J Immunol. 2022 Jan 15;208(2):407-419. doi: 10.4049/jimmunol.2100029. Epub 2021 Dec 29. PMID: 34965963; PMCID: PMC8755605.
  • Biering SB*, Van Dis E*, Wehri E*, Yamashiro LH*, Nguyenla X*, Dugast-Darzacq C, Graham TGW, Stroumza JR, Golovkine GR, Roberts AW, Fines DM, Spradlin JN, Ward CC, Bajaj T, Dovala D, Schulze-Gamen U, Bajaj R, Fox DM, Ott M, Murthy N, Nomura DK, Schaletzky J, Stanley SA. Screening a Library of FDA-Approved and Bioactive Compounds for Antiviral Activity against SARS-CoV-2. ACS Infect Dis. 2021 Aug 13;7(8):2337-2351. doi: 10.1021/acsinfecdis.1c00017. Epub 2021 Jun 15. PMID: 3412
  • Jack A, Ferro LS, Trnka MJ, Wehri E, Nadgir A, Nguyenla X, Fox D, Costa K, Stanley S, Schaletzky J, Yildiz A. SARS-CoV-2 nucleocapsid protein forms condensates with viral genomic RNA. PLoS Biol. 2021 Oct 11;19(10):e3001425. doi: 10.1371/journal.pbio.3001425. PMID: 34634033; PMCID: PMC8553124.
  • Nguyenla X*, Wehri E*, Van Dis E*, Biering SB*, Yamashiro LH*, Stroumza J, Dugast-Darzacq C, Graham T,  Stanley SA, Schaletzky J. Discovery of SARS-CoV-2 antiviral synergy between remdesivir and approved drugs in human lung cells. bioRxiv. 2020 Sept 18; doi: https://doi.org/10.1101/2020.09.18.302398

Publications